ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
businesswire.com
news
2022-06-01 00:00:00

June 01, 2022 04:15 PM Eastern Daylight Time BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. ('ANI' or the 'Company') (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration ('FDA') approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg.



ANI's Fludrocortisone Acetate Tablets are the generic version of the Reference Listed Drug (RLD) FlorinefÂ®. The current annual U.S. market for Fludrocortisone Acetate Tablets, 0.
